DWA
CCXI

Dorsey Wright & Associates’s ChemoCentryx, Inc. CCXI Stock Holding History

Dorsey Wright & Associates’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-585
Closed -$8K – 347
2019
Q1 		$8K Sell
585
-585
-50% -$6.69K ﹤0.01% 242
2018
Q4 		$13K Buy
1,170
+195
+20% +$2.06K ﹤0.01% 234
2018
Q3 		$12K Buy
+975
New +$11.7K ﹤0.01% 266

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dorsey Wright & Associates's CCXI Position: Q2 2019 in Review

Dorsey Wright & Associates sold out of ChemoCentryx, Inc. (CCXI) in Q2 2019, closing a stake of 585 shares — an estimated $8K sold.

Dorsey Wright & Associates first reported a position in CCXI in Q3 2018 and held it in 3 quarters. The position peaked at $13K in Q4 2018. 117 funds tracked by Wall St. Rank hold CCXI as of Q2 2019.

  • Dorsey Wright & Associates reported no remaining ChemoCentryx, Inc. position as of Q2 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 585 ChemoCentryx, Inc. shares in Q2 2019, an estimated $8K.
  • Dorsey Wright & Associates first reported a position in ChemoCentryx, Inc. in Q3 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's ChemoCentryx, Inc. position peaked at $13K in Q4 2018.
  • 117 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2019.

Based on Dorsey Wright & Associates's 13F filing for Q2 2019, filed 2 Jul 2019.